Lauric Acid Overcomes Hypoxia-Induced Gemcitabine Chemoresistance in Pancreatic Ductal Adenocarcinoma
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24087506 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Tadataka Takagi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Pathology, Nara Medical University, Kashihara 634-8521, Japan. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, Culture, Sports, Science and Technology.
Abstract (Originalsprache)
Although gemcitabine (GEM) is widely used in chemotherapy for pancreatic ductal adenocarcinoma (PDA), drug resistance restricts its clinical effectiveness. To examine the mechanism of GEM resistance, we established two GEM-resistant cell lines from human PDA cells by continuous treatment with GEM and CoCl2-induced chemical hypoxia. One resistant cell line possessed reduced energy production and decreased mitochondrial reactive oxygen species levels, while the other resistant cell line possessed increased stemness. In both cell lines, ethidium bromide-stained mitochondrial DNA levels decreased, suggesting mitochondrial DNA damage. Inhibition of hypoxia-inducible factor-1α in both cell lines did not restore the GEM sensitivity. In contrast, treatment of both cell types with lauric acid (LAA), a medium-chain fatty acid, restored GEM sensitivity. These results suggest that decreased energy production, decreased mitochondrial reactive oxygen species levels, and increased stemness associated with mitochondrial damage caused by GEM lead to GEM resistance, and that hypoxia may promote this process. Furthermore, forced activation of oxidative phosphorylation by LAA could be a tool to overcome GEM resistance. Clinical verification of the effectiveness of LAA in GEM resistance is necessary in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Pathology, Nara Medical University, Kashihara 634-8521, Japan.
- Department of Surgery, Nara Medical University, Kashihara 634-8522, Japan.
- Jiangsu Province Key Laboratory of Neuroregeneration, Nantong University, 19 Qixiu Road, Nantong 226001, China.
- Department of Biochemistry and Molecular Biology, Nihon University School of Dentistry at Matsudo, Matsudo 271-8587, Japan.
- Department of Pharmacology, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences, Chennai 600077, India.
ORCID-Profile: Ujjal Kumar Bhawal, Hiroki Kuniyasu
Förderung
- Ministry of Education, Culture, Sports, Science and Technology
Zitieren
APA
Takagi, T., Fujiwara-Tani, R., Mori, S., Kishi, S., Nishiguchi, Y., Sasaki, T., Ogata, R., Ikemoto, A., Sasaki, R., Ohmori, H., Luo, Y., Bhawal, U. K., Sho, M., & Kuniyasu, H. (2023). Lauric Acid Overcomes Hypoxia-Induced Gemcitabine Chemoresistance in Pancreatic Ductal Adenocarcinoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24087506
Vancouver
Takagi T, Fujiwara-Tani R, Mori S, Kishi S, Nishiguchi Y, Sasaki T, et al. Lauric Acid Overcomes Hypoxia-Induced Gemcitabine Chemoresistance in Pancreatic Ductal Adenocarcinoma. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24087506
BibTeX
@article{Takagi2023,
author = {Takagi, Tadataka and Fujiwara-Tani, Rina and Mori, Shiori and Kishi, Shingo and Nishiguchi, Yukiko and Sasaki, Takamitsu and Ogata, Ruiko and Ikemoto, Ayaka and Sasaki, Rika and Ohmori, Hitoshi and Luo, Yi and Bhawal, Ujjal Kumar and Sho, Masayuki and Kuniyasu, Hiroki},
title = {Lauric Acid Overcomes Hypoxia-Induced Gemcitabine Chemoresistance in Pancreatic Ductal Adenocarcinoma},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24087506}
}
EUVIMED